YASMIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Yasmin, and when can generic versions of Yasmin launch?
Yasmin is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in YASMIN is drospirenone; ethinyl estradiol. There are eleven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Yasmin
A generic version of YASMIN was approved as drospirenone; ethinyl estradiol by DR REDDYS LABS SA on September 7th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for YASMIN?
- What are the global sales for YASMIN?
- What is Average Wholesale Price for YASMIN?
Summary for YASMIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Clinical Trials: | 36 |
| Drug Prices: | Drug price information for YASMIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for YASMIN |
| What excipients (inactive ingredients) are in YASMIN? | YASMIN excipients list |
| DailyMed Link: | YASMIN at DailyMed |
Recent Clinical Trials for YASMIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Women's Hospital School Of Medicine Zhejiang University | Phase 4 |
| Inonu University | N/A |
| University of North Carolina, Chapel Hill | Phase 2 |
Paragraph IV (Patent) Challenges for YASMIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| YASMIN | Tablets | drospirenone; ethinyl estradiol | 3 mg/0.03 mg | 021098 | 1 | 2005-01-07 |
US Patents and Regulatory Information for YASMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | YASMIN | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 021098-001 | May 11, 2001 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for YASMIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | YASMIN | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 021098-001 | May 11, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | YASMIN | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 021098-001 | May 11, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | YASMIN | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 021098-001 | May 11, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for YASMIN
See the table below for patents covering YASMIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Eurasian Patent Organization | 001947 | СПОСОБ ПОЛУЧЕНИЯ ДРОСПИРЕНОНА (6b,7b;15b,16b-ДИМЕТИЛЕН-3-ОКСО-17a-ПРЕГН-4-ЕН-21,17-КАРБОЛАКТОНА, DRSP) И 6b,7b;15b,16b-ДИМЕТИЛЕН-5b-ГИДРОКСИ-3-ОКСО-17a-АНДРОСТАН-21,17-КАРБОЛАКТОН (ZK 90965) В КАЧЕСТВЕ ПРОМЕЖУТОЧНОГО ПРОДУКТА (PROCESS FOR PRODUCING DROSPIRENONE (6beta, 7beta, 15beta, 16beta-DIMETHYLENE-3-OXO-17alpha-PREGN-4-EN-21,17-CARBOLACTONE, DRSP) AND 6beta, 7beta, 15beta, 16beta-DIMETHYLENE-5beta-3-OXO-17alpha-ANDROSTANE-21,17-CARBOLACTONE (ZK 90965) AS INTERMEDIATES) | ⤷ Sign Up |
| European Patent Office | 1149841 | Procédé de production de 6B,7B;15B,16B-diméthylene-5B-hydroxy-3-oxo-17alpha-androstane-21,17-carbolactone (Process for the production of 6B,7B;15B,16B-dimethylene-5B-hydroxy-3-oxo-17alpha-androstane-21,17-carbolactone) | ⤷ Sign Up |
| Hong Kong | 1021190 | ⤷ Sign Up | |
| Denmark | 0918791 | ⤷ Sign Up | |
| Poland | 331530 | ⤷ Sign Up | |
| New Zealand | 517845 | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | ⤷ Sign Up |
| Estonia | 05317 | Etin l stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for YASMIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1214076 | 49/2008 | Austria | ⤷ Sign Up | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612 |
| 2588114 | LUC00227 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022 |
| 1380301 | CA 2009 00017 | Denmark | ⤷ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629 |
| 0918791 | PA2006009 | Lithuania | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONUM; NAT. REGISTRATION NO/DATE: LT/1/06/0520/001, 2006 07 10 LT/1/06/0520/002, 2006 07 10 LT/1/06/0520/003, 2006 07 10 LT/1/06/0520/004 20060710; FIRST REGISTRATION: RVG 31781 20050804 |
| 1214076 | SZ 49/2008 | Austria | ⤷ Sign Up | PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON |
| 1214076 | C01214076/01 | Switzerland | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 0398460 | SPC/GB04/032 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
